Pfizer stops developing weight loss pill

Copyright © HT Digital Streams Limit all rights reserved. Jared S. Hopkins, The Wall Street Journal 1 Min Read 14 Apr 2025, 06:15 Ist Pfizer said a study subject developed a liver injury that may have been caused by the weight loss pill. Photo: Bloomberg News Saamwarke Danuglipron was the latest drug investors hoping to enter the obesity market. The decision Pfizer stops the development of its experimental weight loss pill, as the emerging obesity medicine market remains beyond the reach of the drug giant. The company said on Monday that the downturn came after it checked clinical data, and a study subject developed a liver damage that was possibly caused by the middle, Danuglipron. The key point that stops the development of the drug means that Pfizer is still unable to get a cut from the white-hot obesity market, which according to analysts can reach $ 100 billion by the end of the decade. Investors, who were nice to Pfizer’s pipeline, waited for Pfizer’s results on the study. “While we are disappointed to stop the development of Danuglipron, we are still committed to evaluating and promoting promising programs in an effort to bring innovative new medicines to patients,” said Chris Boshoff, head of Pfizer’s scientific officer. Eli Lilly, Novo Nordisk and other companies also test pills that can help people lose weight. The context is Pfizer’s second run to get its weight loss pill on the market. In 2023, Pfizer stopped a study of a twice a day version of Danuglipron after being disappointing test results in which there were too many side effects. In his latest iteration, Pfizer said that his once daily version of Danuglipron achieved its goals in a dosing study, but after reviewing the clinical data of the program, they would stop developing the drug. The company said the liver injury’s liver injury was resolved after the patient stopped taking Danuglipron. Pfizer refused to provide additional details on the liver damage. The shares of the market reaction company have dropped more than half of its pandemic highlights and CEO Albert Bourla wants to reverse the fate of the company. Write to Jared S. Hopkins at jared.hopkins@wsj.com, catch all the corporate news and updates on live currency. Download the Mint News app to get daily market updates and live business news. More Topics #Pfizer Mint Specials